Gilead's Vitekta Gets Approval in European Union Wall Street Journal Meanwhile, Gilead said its Phase 3 study of idelalisib in combination with rituximab in previously treated chronic lymphocytic leukemia patients who weren't fit for chemotherapy was accepted for presentation at the Annual Meeting of the American ... |
